Intuitive Surgical, Inc.

As of October 24, 2025, Intuitive Surgical, Inc. is considered expensive due to high valuation ratios compared to peers, despite a strong 3-year return of 148.11%, although its year-to-date return of 4.70% lags behind the S&P 500's 15.47%.

As of October 24, 2025, Intuitive Surgical's technical trend is neutral with mixed signals, showing mild bullishness on the weekly MACD and bullish conditions on Bollinger Bands, but bearish signals on daily moving averages and KST, while outperforming the S&P 500 in the short term but lagging year-to-date and over the past year.

As of October 24, 2025, Intuitive Surgical, Inc. is considered expensive and overvalued with high valuation ratios, despite strong recent performance, suggesting it may not be a prudent investment at current levels.

As of October 24, 2025, Intuitive Surgical's technical trend is neutral with mixed signals, showing mild bullishness in the weekly MACD and Bollinger Bands, but bearish indicators in daily moving averages and KST, while it has outperformed the S&P 500 recently but underperformed over longer periods, suggesting a cautious approach.

As of October 24, 2025, Intuitive Surgical, Inc. is considered expensive with high valuation ratios, including a P/E of 80 and an EV to EBITDA of 66.13, despite recent strong short-term performance, as its year-to-date return of 4.70% lags behind the S&P 500's 15.47%.

As of October 10, 2025, Intuitive Surgical, Inc. is fairly valued with a high P/E ratio of 80, but has underperformed the S&P 500 with a year-to-date return of -17.70%, indicating potential challenges in justifying its premium compared to peers like Abbott Laboratories and Thermo Fisher Scientific.

As of August 4, 2025, Intuitive Surgical, Inc. is in a bearish trend, indicated by negative technical indicators and underperformance against the S&P 500, with year-to-date and one-year returns of -16.50% and -9.60%, respectively.

As of July 22, 2025, Intuitive Surgical, Inc. is considered expensive and overvalued due to its high P/E ratio of 80 and underperformance with a year-to-date return of -16.50%, despite strong ROCE and ROE metrics.

As of June 27, 2025, the technical trend has shifted to bullish, supported by strong indicators such as a bullish weekly MACD, positive daily moving averages, and favorable Bollinger Bands, along with solid performance relative to the S&P 500 over the past year and three years.

As of November 5, 2024, Intuitive Surgical, Inc. is considered very expensive and overvalued, with a P/E ratio of 80 and a PEG ratio of 3.60, indicating that its high price is not justified by its growth expectations or returns, especially as it has underperformed the S&P 500 recently.

As of June 20, 2025, the trend has shifted to mildly bullish, supported by Dow Theory, despite mixed signals from MACD, moving averages, and Bollinger Bands, indicating a cautiously optimistic outlook.

As of March 2022, the management team of Intuitive Surgical, Inc. includes Dr. Craig Barratt (Chairman), Dr. Gary Guthart (CEO), and several independent directors: Mr. Joseph Beery, Ms. Amal Johnson, Dr. Don Kania, Dr. Amy Ladd, and Mr. Keith Leonard. They are responsible for the company's strategic direction and operations.

Intuitive Surgical, Inc. designs and manufactures da Vinci Surgical Systems and related instruments in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $2.25 billion and a net profit of $704 million, with a market cap of approximately $183.55 billion.

As of Jun 18, Intuitive Surgical, Inc. has a market capitalization of $183.55 billion, with net sales of $8.71 billion and a net profit of $2.49 billion over the latest four quarters.